Actavis receives FDA marketing approval for generic Cozaar

Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Losartan Potassium Tablets, USP, a generic version of Merck's Cozaar® in 25 mg, 50 mg and 100 mg strength.  Losartan Potassium Tablets, USP were developed by Actavis R&D in Iceland.

Losartan Potassium Tablets, USP had US sales of approximately $940 million for the 12 months ending June 30, 2010 according to IMS Health.    

SOURCE Actavis Inc.